血清PRDX3在肝癌高风险人群中检测的临床价值

目的探讨过氧化物酶3（peroxiredoxin 3,PRDX3）在肝癌高风险人群（不同类型HBV感染）患者血清中的表达水平及临床意义。方法采用酶联免疫吸附法（ELISA）对慢性乙型肝炎、乙肝后肝硬化、乙肝相关肝癌患者及正常对照组的血清PRDX3进行检测,另所有受试者均进行AFP、肝功能以及肝纤维谱测定;同时分析肝癌患者上述检测指标及临床病例因素与血清PRDX3浓度的关系。结果不同类型乙型肝炎病毒感染者血清PRDX3含量均显著高于正常对照组（P〈0.01）。肝癌患者血清PRDX3含量显著高于其他组（P〈0.01）,ROC曲线分析显示,PRDX3和AFP的曲线下面积AUC分别为0.912和0.836;Spearman相关分析表明肝癌患者血清PRDX3与碱性磷酸酶（ALP）、甲胎蛋白（AFP）、透明质酸（HA）的相关性较高（r均大于0.60,P均〈0.01）。肝癌患者血清PRDX3浓度不受HBV-DNA载量、肿瘤直径、门静脉转移的影响,而与肝病患者的TNM分期密切相关（r=0.898,P〈0.01）。结论血清PRDX3的测定有助于乙肝相关性肝癌的诊断,并且对乙肝相关性肝癌的早期发生起到一定的预警作用。

The clinical significance of serum PRDX3 in populations with high risk of liver cancer

Objective To investigate the level and clinical significance of serum peroxiredoxin 3（ PRDX3） in patients with high risk of liver cancer（ infected with HBV）. Methods Serum PRDX3 was detected in patients with chronic hepatitis B,cirrhosis,HCC and in normal controls by enzyme-linked immunosorbent assay（ ELASA）.Other serum markers such as AFP,liver function and fibrosis indexes were also detected. The relationship between PRDX3 and above serum markers as well as some clinical and pathological factors was analyzed in patients with hepatocelluar carcinoma（ HCC）. Results The PRDX3 level in patients infected with HBV was significantly higher than that in normal controls（ P 〈0. 01）. The PRDX3 level in patients with HCC was significantly higher than that in other groups（ P 〈0. 01）; the area under the curve of PRDX3 and AFP for diagnosis of HCC was 0. 912 and0. 836,respectively. PRDX3 had close correlation with ALP,AFP and HA（ all r 0. 60,all P 〈0. 01）. PRDX3 level was associated with TNM stage other than HBV DNA virus loads,tumor size and portal vein invasion. Conclusion Serum PRDX3 level generally rises in patients infected with HBV,especially dramatically higher in patients with HCC. PRDX3 is a potential effective serum marker for HCC diagnosis.